Designing a randomized phase I/II prostate cancer chemoprevention trial using 1α-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D 3

Cancer Journal

Volumn 10, Issue 6, 2004, Pages 357-367

  Packianathan, S ^a   Mehta, Rajendra G ^b   Mehta, Rajeshwari R ^b   Hall, William H ^a   Boerner, Philip S ^a   Beckett, Laurel A ^a   Vijayakumar, Srinivasan ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemoprevention; Phase I II; Prostate cancer; Radiation therapy; Randomized clinical trial; Vitamin D

Indexed keywords

1 ALPHA HYDROXY 24 ETHYL CHOLECALCIFEROL; COLECALCIFEROL DERIVATIVE; UNCLASSIFIED DRUG; 1 HYDROXYVITAMIN D5; 1-HYDROXYVITAMIN D5; ANTINEOPLASTIC AGENT; HYDROXYCOLECALCIFEROL; TUMOR MARKER;

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; FINANCIAL MANAGEMENT; HUMAN; MALE; MORBIDITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; METHODOLOGY; PATIENT SELECTION; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DOUBLE-BLIND METHOD; HUMANS; HYDROXYCHOLECALCIFEROLS; MALE; PATIENT SELECTION; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TUMOR MARKERS, BIOLOGICAL;

EID: 15744398245     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200411000-00005     Document Type: Article

References (88)

1. Sakr WA, Grignon DJ, Haas GP et al. Age and racial distribution of prostatic intraepithelial neoplasia. Eur J Urol 1996;30:138-144.
2. Sakr WA, Grignon DJ, Crissman JD et al. High-grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-443.
3. Feigl P, Blumenstein B, Thompson IM et al. Design of the prostate cancer prevention trial (PCPT). Cont Clin Trials 1995;16:150-163.
4. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224; Epub 2003 Jun 24.
5. Thompson IM, Tangen C, Goodman P. The prostate cancer prevention trial: design, status, and promise. World J Urol 2003;21:28-30.
6. Klein EA, Thompson IM, Lippman SM et al. SELECT: The selenium and vitamin E cancer prevention trial: rationale and design. Prostate Cancer Prostatic Dis 2000;3:145-151.
7. Klein EA, Thompson IM, Lippman SM et al. SELECT: the selenium and vitamin E cancer prevention trial. Urol Oncol 2003;21:59-65.
8. Lee JJ, Lieberman R, Sloan JA et al. Design considerations for efficient prostate cancer chemoprevention trials. Urology 2001;57:205-212.
9. Trock BJ. Validation of surrogate endpoint markers in prostate cancer chemoprevention trials. Urology 2001;57[suppl]:241-247.
10. Lieberman R, Bermejo C, Akaza H et al. Progress in prostate cancer chemoprevention: modulators of promotion and progression. Urology 2001;58:835-842.
11. Langman M, Boyle P. Chemoprevention of colorectal cancer. Gut 1998;43:578-585.
12. Majewski S, Kumer A, Jablonska S. Vitamin D analogs in cutaneous malignancies. Curr Pharm Des 2000;6:829-838.
13. Shen Q, Brown PH. Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia 2003;8:45-73.
14. Peehl DM, Krishnan AV, Feldman D. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 2003;133:2461S-2469S.
15. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995;16:200-257.
16. 5 clinical trial: a review. 2004; submitted for publication.
17. Sporn MB. Approaches to prevention of epithelial cancer during the pre-neoplastic period. Cancer Res 1976;36:2689-2701.
18. Kakizoe T. Chemoprevention of cancer: focusing on clinical trials. Jpn J Clin Oncol 2003;33:421-442.
19. Sun S-Y, Hail N Jr, Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 2004;96:662-672.
20. Kelloff GJ, Boone CW, Steele VE et al. Mechanistic considerations in the evaluation of chemopreventive data. IARC Scientific Pub 1996;139:203-219.
21. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin 2004;54:150-180.
22. Lamm DL, Riggs DR, Shriver JS et al. Mega dose vitamins in bladder cancer: a double blind clinical trial. J Urol 1994;151:21-26.
23. Studer UE, Jenzer S, Biedermann C et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors: final analysis of a prospective, randomized, multi-center trial in Switzerland. Eur Urol 1995;28:284-290.
24. Alberts S, Blute M. Chemoprevention for prostate carcinoma: the role of flutamide in patients with prostatic intraepithelial neoplasia. Urology 2001;57:188-190.
25. Clark LC, Marshall JR. Randomized controlled chemoprevention trials in populations at very high risk for prostate cancer: elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia. Urology 2001;57:185-187.
26. Blot WJ, Li J-Y, Taylor PR et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-1492.
27. Tsubono Y, Okubo S, Hayashi M et al. A randomized controlled trial for chemoprevention of gastric cancer in high risk Japanese population: study design, feasibility, and protocol modification. Jpn J Cancer Res 1997;88:344-349.
28. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986;315:1575-1578.
29. Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-807.
30. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial: Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.
31. Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Breast Cancer Res Treat 2001;65:125-134.
32. Stich HF, Hornby AP, Mathew B et al. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988;40:93-101.
33. Chiesa F, Tradati N, Marazza M et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem Suppl 1993;17F:255-261.
34. Meyskens FL, Emerson SS, Pelot D et al. Dose de-escalation chemoprevention trial of α-difluoromethylornithine in patients with colon polyps. J. Natl Cancer Inst 1994;85:732-736.
35. Calle EE, Miracle-McMahill HL, Thun MJ et al. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of post-menopausal women. J. Natl Cancer Inst 1995;87:517-523.
36. Cheng AL, Lin JK, Hsu MMM et al. Phase 1 clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-2900.
37. Heinonen OP, Huttuner JK, Albanes D. The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-1035.
38. Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-1155.
39. Keegan P, Loughman BE. Early clinical trials of chemopreventive and biologic agents: designs, populations, and endpoints. Urology 2001;57:216-219.
40. The α-Tocopherol β-Carotene Cancer Prevention Study Group. The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-1035.
41. Green A, William G, Neale R et al. Daily sunscreen application and β-carotene supplementation in prevention of basal cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999;354:723-729.
42. Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
43. Phillips RK, Wallace MH, Lynch PM et al. The FAP Study Group: a randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857-860.
44. Hong WK, Lippman SM, Itri LM et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
45. Baum M, Buzdar A, Cuzick J et al. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-1810.
46. Lam S, MacAulay C, Le Riche JC et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002;94:1001-1009.
47. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890.
48. McConnell JD, Roehrborn CG, Bautista OM et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-2398.
49. Post MJ, Laham R, Sellke FW et al. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res 2001;49:522-531.
50. Schatzkin A, Freedman LS, Schiffman MH et al. Validation of intermediate endpoints in cancer research. J Natl Cancer Inst 1990;82:1746-1752.
51. Schatzkin A, Freedman LS, Dorgan J et al. Surrogate endpoints in cancer research: a critique. Cancer Epidemiol Biomarkers Prev 1996;5:947-953.
52. Baker SG, Kramer SK. A perfect correlate does not a surrogate make. BMC Med Res Methodol 2003;3:16-20.
53. Misset JL, Mathe G, Santelli G et al. Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment. Cancer Detect Prev 1986;9:167-170.
54. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival study (4S). Lancet 1994;344:1383-1389.
55. Mitchell MF, Hittelman WN, Hong WK et al. The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. Cancer Epidemiol Biomarkers Prev 1994;3:619-626.
56. Deyton L. Importance of surrogate markers in evaluation of antiviral therapy for HIV. JAMA 1999;280:159-160.
57. Katz R. Biomarkers and surrogate biomarkers: an FDA perspective. J Am Soc Neurotherapeutics 2004;1:189-195.
58. Fleming TR, Prentice RL, Pepe MS et al. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat Med 1994;13:955-968.
59. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 1998;54:1014-1029.
60. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-440.
61. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 1996;125:605-613.
62. Berger VW. Does the Prentice criterion validate surrogate endpoints? Stat Med 2004;23:1571-1578.
63. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:2321-2333.
64. Abdalla I, Basu A, Hellman S. An evidence-based analysis of the management of localized prostate cancer. Cancer J 2002;8:40-46.
65. Zelefsky MJ, Lyass O, Fuks Z et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 1998;16:3380-3385.
66. Connell PP, Ignacio L, Haraf D et al. Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. J Clin Oncol 2001;19:54-61.
67. Moul JW, Connelly RR, Lubeck DP et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the center for prostate disease research and cancer of the prostate strategic urologic research endeavor databases. J Urol 2001;166:1322-1327.
68. Mehta RG, Moriarty RM, Mehta RR et al. Prevention of preneoplastic mammary lesion development by a novel vitamin D analog 1α(hydroxy) vitamin D5. J Natl Cancer Inst 1997;89:212-219.
69. Lieberman R. Prostate cancer chemoprevention: strategies for designing efficient clinical trials. Urology 2001;57[suppl]:224-229.
70. 5 versus placebo: a tolerance-finding and intermediate biomarker response-seeking study. UC Davis IRB Protocol #200412214-1, 2004.
71. Zuger A. A big study yields big questions. N Engl J Med 2003;349:213-214.
72. Osborn JL, Schwartz GG, Smith DC et al. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1995;1:195-198.
73. Beer TM, Eilers KM, Garzotto M et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003;21:123-128.
74. Beer TM, Eilers KM, Garzotto M et al. Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma. Cancer 2004;100:758-763.
75. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
76. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-108.
77. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
78. Moul JW, Fowler EJ Jr. Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003. Urology 2003;62[suppl 1]:20-28.
79. Sun L, Moul JW, Wu H et al. Natural history of prostate cancer in 3605 CPDR patients receiving radical prostatectomy and factors affecting post-treatment clinical metastasis in PSA era [abstract 1489]. J Urol 2003;169:398.
80. Hinkle GH, Burgers JK, Neal CE et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998;83:739-747.
81. ASTRO Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
82. Jani AB, Chen MH, Vaida F et al. PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention. Urology 1999;54:700-705.
83. Shipley WU, Thames HD, Sandler HM et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999;281:1598-1604.
84. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-826.
85. Magee JA, Araki T, Patil S et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001;61:5692-5696.
86. Welsh JB, Sapinoso LM, Su Al et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-5978.
87. Luo J-H, Yu YP, Cieply K et al. Gene expression analysis of prostate cancers. Mol Carcin 2002;33:25-35.
88. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-974.